Search

Displaying results 5871 - 5880 of 10000 in total
  1. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. … Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein.

  2. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [F79] It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. … [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.

  3. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

  4. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.

  5. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.

  6. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. … RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in

  7. Drug

    FB-825

    go.drugbank.com/drugs/DB17598
    Investigational

    FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells.

  8. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  9. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

  10. Drug

    Vemtoberant

    go.drugbank.com/drugs/DB21607
    Investigational

    Vemtoberant has a monoisotopic molecular weight of 619.2 Da. … Vemtoberant is a small molecule drug.